Citations 191

What's in a name: are menopausal “hot flashes” a symptom of menopause or a manifestation of neurovascular dysregulation?

Menopause | January 29, 2018 | Volume: 25 | Issue: 6 | Pages: 700-703

10.1097/gme.0000000000001065 | PMID 29381665

Abstract Hot flashes have typically been classified as “symptoms of menopause” that should be tolerated or treated until they resolve. However, mounting evidence points to hot flashes as a manifestation of one or several underlying pathophysiological processes. Associations exist between the presence, timing of onset, severity, and duration of hot flashes, and the risk of several neurological (affecting sleep, mood, and cognition) and cardiovascular conditions. In addition, four consistent patterns of vasomotor disturbances have been identified across different countries, making it unlikely that these patterns are solely explained by socioeconomic or cultural factors. The changing hormonal environment of menopause may unmask differences in the autonomic neurovascular control mechanisms that put an individual woman at risk for chronic conditions of aging. These differences may have a genetic basis or may be acquired across the life span and are consistent with the variability of the clinical manifestations of aging observed in women after bilateral oophorectomy. It is time to investigate the pathophysiological mechanisms underlying the four patterns of vasomotor symptoms more closely, and to shift from describing hot flashes as symptoms to be tolerated to manifestations of an underlying autonomic neurovascular dysregulation that need to be addressed.
Parkinson disease with and without Dementia: A prevalence study and future projections

Movement Disorders | January 22, 2018 | Volume: 33 | Issue: 4 | Pages: 537-543

10.1002/mds.27277 | PMID 29356127

ABSTRACTBackground: Limited population‐based information is available on the co‐occurrence of dementia and PD. However, projecting the prevalence of PD with and without dementia during the next 50 years is crucial for planning public‐health and patient‐care initiatives.Objectives: The objective of this study was to project the prevalence of PD with and without dementia in the United States by 2060.Methods: We used the Rochester Epidemiology Project medical records‐linkage system to identify all persons with PD with or without dementia residing in Olmsted County, Minnesota, on January 1, 2006. A movement disorders specialist reviewed the complete medical records of each person to confirm the presence of PD. We calculated the age‐ and sex‐specific prevalence of PD with and without dementia and projected U.S. prevalence through 2060.Results: We identified 296 persons with PD with and without dementia on the prevalence date (187 men, 109 women); the overall prevalence increased with age from 0.01% (30‐39 years) to 2.83% (≥90 years). The prevalence of PD without dementia increased with age from 0.01% (30‐39 years) to 1.25% (≥90 years). The prevalence of PD with dementia increased with age from 0.10% (60‐69 years) to 1.59% (≥90 years). The prevalence was higher in men than in women for all subtypes and all age groups. We project by 2060 an approximate doubling of the number of persons with PD without dementia and a tripling of the number of persons with PD with dementia in the United States.Conclusions: The prevalence of PD with and without dementia increases with age and is higher in men than women. We project that the number of persons with PD in the United States will increase substantially by 2060. © 2018 International Parkinson and Movement Disorder Society
Is multiple system atrophy an infectious disease?

Annals of Neurology | January 2, 2018 | Volume: 83 | Issue: 1 | Pages: 10-12

10.1002/ana.25132 | PMID 29293269

Cardiovascular and metabolic morbidity after hysterectomy with ovarian conservation: a cohort study

Menopause | December 29, 2017 | Volume: 25 | Issue: 5 | Pages: 483-492

10.1097/gme.0000000000001043 | PMID 29286988

Abstract Objective: The aim of the study was to determine the long-term risk of cardiovascular disease and metabolic conditions in women undergoing hysterectomy with bilateral ovarian conservation compared with age-matched referent women. Methods: Using the Rochester Epidemiology Project records-linkage system, we identified 2,094 women who underwent hysterectomy with ovarian conservation for benign indications between 1980 and 2002 in Olmsted County, Minnesota. Each woman was age-matched (±1 y) to a referent woman residing in the same county who had not undergone prior hysterectomy or any oophorectomy. These two cohorts were followed historically to identify de novo cardiovascular or metabolic diagnoses. We estimated hazard ratios (HRs) and 95% CIs using Cox proportional hazards models adjusted for 20 preexisting chronic conditions and other potential confounders. We also calculated absolute risk increases and reductions from Kaplan–Meier estimates. Results: Over a median follow-up of 21.9 years, women who underwent hysterectomy experienced increased risks of de novo hyperlipidemia (HR 1.14; 95% CI, 1.05-1.25), hypertension (HR 1.13; 95% CI, 1.03-1.25), obesity (HR 1.18; 95% CI, 1.04-1.35), cardiac arrhythmias (HR 1.17; 95% CI, 1.05-1.32), and coronary artery disease (HR 1.33; 95% CI, 1.12-1.58). Women who underwent hysterectomy at age ≤35 years had a 4.6-fold increased risk of congestive heart failure and a 2.5-fold increased risk of coronary artery disease. Conclusions: Even with ovarian conservation, hysterectomy is associated with an increased long-term risk of cardiovascular and metabolic conditions, especially in women who undergo hysterectomy at age ≤35 years. If these associations are causal, alternatives to hysterectomy should be considered to treat benign gynecologic conditions.
Prevalence of and indications for antipsychotic use in Parkinson's disease

Movement Disorders | December 26, 2017 | Volume: 33 | Issue: 2 | Pages: 325-328

10.1002/mds.27256 | PMID 29278275

ABSTRACTBackground: The prevalence of patients with PD taking antipsychotics is unknown.Objective: To measure the prevalence of patients with PD taking antipsychotics.Methods: We used the medical records‐linkage system of the Rochester Epidemiology Project to study the use of antipsychotic medication in all persons with Parkinson disease in Olmsted County, Minnesota on 1 January 2006.Results: There were 296 patients with PD in Olmsted County on 1 January 2006. The overall prevalence of antipsychotic use was 9.8% (29 of 296); 95.5% (28 of 29) of the patients had dementia when initiating antipsychotics. The most frequent indication (71.4%; 20 of 28) was psychosis or behavior threatening to the patient or others.Conclusions: The prevalence of antipsychotic use in patients with PD is lower than expected from previously reported cumulative incidences. Dementia is highly prevalent in those starting antipsychotics. Most of the patients on antipsychotics had a reasonable risk‐benefit ratio for taking them. © 2017 International Parkinson and Movement Disorder Society
Data Resource Profile: Expansion of the Rochester Epidemiology Project medical records-linkage system (E-REP)

International Journal of Epidemiology | December 13, 2017 | Volume: 47 | Issue: 2 | Pages: 368-368j

10.1093/ije/dyx268 | PMID 29346555

Cohort profile: the Mayo Clinic Cohort Study of Oophorectomy and Aging-2 (MOA-2) in Olmsted County, Minnesota (USA)

BMJ Open | November 20, 2017 | Volume: 7 | Issue: 11 | Pages: e018861

10.1136/bmjopen-2017-018861 | PMID 29162577

Purpose This cohort study was established to investigate the effects of unilateral and bilateral oophorectomy on the ageing processes in women. Participants We used the records-linkage system of the Rochester Epidemiology Project (REP, http://www.rochesterproject.org ) to identify 570 women who underwent unilateral oophorectomy and 1653 women who underwent bilateral oophorectomy in Olmsted County, Minnesota from 1988 through 2007 (20 years). Each woman was matched by age (±1 year) to a population-based referent woman who had not undergone any oophorectomy (570 referent women) or bilateral oophorectomy (1653 referent women). These four cohorts are being followed to assess morbidity and mortality and to study imaging and biological markers related to ageing. Findings to date An extensive medical record abstraction using the REP has been completed for each woman to obtain demographic, reproductive and adult life characteristics and extensive clinical information about the surgical procedure and subsequent oestrogen replacement therapy (or other sex steroid therapy). The cohorts have been used to date to study the accumulation of multiple chronic conditions following bilateral oophorectomy in women with or without chronic conditions at the time of the oophorectomy (or index date). From the cohorts, we have also derived a sample of 128 pairs of women for a case–control study linking adverse childhood or adult experiences to the risk of bilateral oophorectomy. Future plans We hypothesise that the abrupt hormonal changes caused by bilateral oophorectomy in younger women have a major effect on the ageing processes across the full body. Therefore, we plan to investigate the risk of a wide range of chronic conditions following bilateral oophorectomy. Specific studies are underway for kidney diseases, psychiatric diseases and neurological diseases. In addition, we plan to invite a subsample of women from the bilateral oophorectomy cohort to participate in an in-person study involving brain imaging and the collection of biomarkers.
[O2–07–06]: CHANGES IN BRAIN STRUCTURE THREE YEARS AFTER THE END OF MENOPAUSAL HORMONE THERAPIES IN A RANDOMIZED CONTROLLED TRIAL

Alzheimer's & Dementia | October 20, 2017 | Volume: 13 | Issue: 7S_Part_11 | Pages: No page available

10.1016/j.jalz.2017.07.185

The future burden of Parkinson's disease

Movement Disorders | August 7, 2017 | Volume: 33 | Issue: 1 | Pages: 8-9

10.1002/mds.27114 | PMID 28782890

Response to Letter by Friedman on “Incidence and time trends of drug‐induced parkinsonism: A 30‐year population‐based study”

Movement Disorders | June 14, 2017 | Volume: 32 | Issue: 7 | Pages: 1111-1112

10.1002/mds.27051 | PMID 28612941